{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:08:35Z","timestamp":1766268515077},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3679,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1365-2133.2005.06648.x","type":"journal-article","created":{"date-parts":[[2005,8,20]],"date-time":"2005-08-20T02:12:18Z","timestamp":1124503938000},"page":"531-536","source":"Crossref","is-referenced-by-count":79,"title":["Cytokine profiles during infliximab monotherapy in psoriatic arthritis"],"prefix":"10.1093","volume":"153","author":[{"given":"A.","family":"Mastroianni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Minutilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bordignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Trento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"D'Agosto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cordiali-Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Berardesca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,8,5]]},"reference":[{"issue":"Suppl. 28","key":"10.1111\/j.1365-2133.2005.06648.x-BIB1|cit1","first-page":"S71","article-title":"Disease-modifying antirheumatic drug therapy for psoriatic arthritis","volume":"20","author":"Salvarani","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB2|cit2","first-page":"116","article-title":"Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis: a pilot study","volume":"186","author":"Mazzanti","year":"1994","journal-title":"Acta Derm Venereol Suppl"},{"issue":"Suppl.","key":"10.1111\/j.1365-2133.2005.06648.x-BIB3|cit3","first-page":"S92","article-title":"Leflunomide in psoriatic polyarthritis: an Italian pilot study","volume":"44","author":"Scarpa","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"Suppl.","key":"10.1111\/j.1365-2133.2005.06648.x-BIB4|cit4","first-page":"S121","article-title":"Long term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis","volume":"44","author":"Liang","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0140-6736(02)07536-0","article-title":"Immunotherapy for psoriasis: from serendipity to selectivity","volume":"359","author":"Griffiths","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1111\/j.1365-2133.2005.06648.x-BIB7|cit7","first-page":"S91","article-title":"Alefacept reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis","volume":"42","author":"Dinant","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB9|cit9","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor-\u03b1 and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2249.1994.tb06244.x","article-title":"Elevated TNF\u03b1 biological activity in psoriatic skin lesions","volume":"96","author":"Ettehadi","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-4362.1999.00622.x","article-title":"Cytokines in psoriasis","volume":"38","author":"Bonifati","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9%3C1564::AID-ART6%3E3.0.CO;2-M","article-title":"Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?","volume":"41","author":"Felson","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2004.04.012","article-title":"Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment","volume":"51","author":"Langley","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"issue":"Suppl. 28","key":"10.1111\/j.1365-2133.2005.06648.x-BIB15|cit15","first-page":"S122","article-title":"Infliximab for psoriasis and psoriatic arthritis","volume":"20","author":"Antoni","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-TNF \u03b1 therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gut.53.1.70","article-title":"Defective mucosal T cell death is substantially reverted by infiximab in a caspase dependent pathway in Crohn's disease","volume":"53","author":"Di Sabatino","year":"2004","journal-title":"Gut"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000247210","article-title":"Is sustained production of tumor necrosis factor-alpha relevant to the development of pustular psoriasis?","volume":"187","author":"Sagawa","year":"1993","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ard.61.4.298","article-title":"TNF in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors","volume":"61","author":"Mease","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1002\/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2","article-title":"Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis","volume":"43","author":"Danning","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1523-1747.1999.00749.x","article-title":"The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients","volume":"113","author":"Austin","year":"1999","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2005.06648.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1523-1747.2000.00138.x","article-title":"Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2","volume":"115","author":"Fleischmajer","year":"2000","journal-title":"J Invest Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2005.06648.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2005.06648.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:13:09Z","timestamp":1676383989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/153\/3\/531\/6636589"}},"subtitle":["Cytokine profiles and infliximab monotherapy in PsA"],"short-title":[],"issued":{"date-parts":[[2005,8,5]]},"references-count":25,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06648.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8,5]]}}}